Clindamycin
Clindamycin is a topic covered in the Johns Hopkins HIV Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Skin and soft tissue infections caused by streptococci, staphylococci and anaerobes
- Pelvic infections (endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and post-surgical vaginal cuff infections)
- Intra-abdominal infections such as peritonitis and intra-abdominal abscess caused by anaerobes (note: IDSA guideline no longer recommends clindamycin due to increased B. fragilis resistance rate)
- Streptococcus pneumoniae (empyema, pneumonitis, and lung abscess)
- Septicemia (no longer recommended)
- Acne vulgaris (topical gel)
- Bacterial vaginosis in non-pregnant women and pregnant women during the second and third trimesters (intra-vaginal administration)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Alternative treatment of PCP in combination with primaquine
- Alternative treatment of CNS toxoplasmosis in combination with pyrimethamine and leucovorin
- MRSA skin and soft tissue infections
- Necrotizing fasciitis including Fournier gangrene: may be considered in combination with other agents to decrease toxin production caused by MRSA, S. pyogenes, C. perfringens
- Oral abscess in patients with PCN allergies
- Acute bacterial sinusitis
- Intrapartum prophylaxis for Group B strep; alternative to beta-lactam only if susceptibility testing is done
- Bacterial vaginosis
- Actinomycosis
- Osteomyelitis
- Acute bacterial sinusitis
- Non-severe malaria as part of alternative regimen, especially in pregnancy
- Diphtheria
- Alternative therapy for bebesiosis in combination with quinine
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Skin and soft tissue infections caused by streptococci, staphylococci and anaerobes
- Pelvic infections (endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and post-surgical vaginal cuff infections)
- Intra-abdominal infections such as peritonitis and intra-abdominal abscess caused by anaerobes (note: IDSA guideline no longer recommends clindamycin due to increased B. fragilis resistance rate)
- Streptococcus pneumoniae (empyema, pneumonitis, and lung abscess)
- Septicemia (no longer recommended)
- Acne vulgaris (topical gel)
- Bacterial vaginosis in non-pregnant women and pregnant women during the second and third trimesters (intra-vaginal administration)
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Alternative treatment of PCP in combination with primaquine
- Alternative treatment of CNS toxoplasmosis in combination with pyrimethamine and leucovorin
- MRSA skin and soft tissue infections
- Necrotizing fasciitis including Fournier gangrene: may be considered in combination with other agents to decrease toxin production caused by MRSA, S. pyogenes, C. perfringens
- Oral abscess in patients with PCN allergies
- Acute bacterial sinusitis
- Intrapartum prophylaxis for Group B strep; alternative to beta-lactam only if susceptibility testing is done
- Bacterial vaginosis
- Actinomycosis
- Osteomyelitis
- Acute bacterial sinusitis
- Non-severe malaria as part of alternative regimen, especially in pregnancy
- Diphtheria
- Alternative therapy for bebesiosis in combination with quinine
There's more to see -- the rest of this entry is available only to subscribers.